ROR1 and neoplasm: In this study, to break immunologic tolerance to a self TAA (mROR1 protein), we designed and produced five different recombinant fusion proteins of mROR1 (Figure 1) and investigated their immunogenicity and protective efficacy as an anti-cancer candidate vaccine in fully syngeneic ROR1+ mouse tumor models.